In this study, mutant KRAS was inactivated in KRASG12D, p53KO pancreatic tumor cells to show that upon loss of the KRAS mutation, cells still retained tumorigenic capacity, but lost their ability to evade the adaptive immune system [82]. Here, KRAS is linked to pancreatic neoplasm.